Home » Posts tagged 'AstraZeneca'

AstraZeneca

IP Intensive: Sitting at the Crossroads of Law, Medicine, Business, and Government - A Semester at AstraZeneca

IP Intensive: Sitting at the Crossroads of Law, Medicine, Business, and Government - A Semester at AstraZeneca

I was thrilled when I found out I’d be joining the legal team at AstraZeneca Canada for a semester, as part of Osgoode’s IP Law and Technology Intensive Program. I realized very quickly though that I was joining more than just a legal team - I was joining a culture of interdisciplinary professionals who are […]

IP Intensive: The Business of Innovation - A Semester at AstraZeneca

IP Intensive: The Business of Innovation - A Semester at AstraZeneca

As part of Osgoode’s IP Law and Technology Intensive Program, I had the amazing opportunity to serve a 10-week internship at AstraZeneca Canada under the supervision of AstraZeneca’s Legal Director, Denise Lacombe. My experience has been the most rewarding learning experience that I have had at Osgoode Hall Law School.

IP Intensive: AstraZeneca visits the Supreme Court of Canada

IP Intensive: AstraZeneca visits the Supreme Court of Canada

As part of Osgoode's Intellectual Property Law & Technology Intensive Program, I had the distinct pleasure of working with the Legal Affairs team at AstraZeneca Canada. With a technical background in the life sciences and a keen interest in pursuing a legal career engaged in this field, having the opportunity to gain first hand experience […]

IP Intensive: A Semester at AstraZeneca Canada

IP Intensive: A Semester at AstraZeneca Canada

Last semester, as part of Osgoode's Intellectual Property Law and Technology Intensive Program, I had the opportunity to work with in-house counsel at AstraZeneca Canada. Having previously completed graduate studies in organic chemistry, I had always been very interested in the scientific aspects of the drug development process so I was very excited to have […]

An Unexpected Infringement: There and Back Again

An Unexpected Infringement: There and Back Again

On March 16, 2015, Justice Barnes held that AstraZeneca’s Patent No 1,292,693 (“’693 Patent”), a formulation patent for omeprazole, was valid and infringed by Apotex (2015 FC 322). This decision represents the latest entry in the 22-year old cross-jurisdictional Omeprazole saga between AstraZeneca and Apotex. Because the proceedings were bifurcated, a separate reference for damage […]